The impact of cardiorespiratory fitness on Alzheimer's disease biomarkers and their relationships with cognitive decline.

Paulsen AJ[a,b], Driscoll I[a,b], Breidenbach BM[a,b], Glittenberg MP[a,b], Lose SR[a,b], Ma Y[a], Sager MA[a], Carlsson CM[a,b,c], Gallagher CL[c,d], Hermann BP[b,d], Blennow K[e,f,g,h], Zetterberg H[a,e,f,i,j,k], Asthana S[a,b,c], Johnson SC[a,b], Betthauser TJ[a,b], Christian BT,[l] Cook DB,[m,n], Okonkwo* OC[a,b,c]

[a.] Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, MC2420, Madison, Wisconsin, 53792, USA.

[b.] Wisconsin Alzheimer's Institute, 610 Walnut St, Suite 957, Madison, Wisconsin, 53726, USA.

[c.] Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, 2500 Overlook Terrace, Madison, Wisconsin, USA, 53705.

[d.] Department of Neurology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, Madison, Wisconsin, 53705, USA.

[e.] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Box 100, 405 30 Gothenburg, Mölndal, Sweden.

[f.] Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, SE-43180, Göteborg, Sweden.

[g.] Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, 47 Bd de l'Hôpital, 75013, Paris, France.

[h.] Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, No.96, JinZhai Road Baohe District, Hefei, Anhui, 230026, P.R. China.

[i.] Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.

[j.] UK Dementia Research Institute at UCL, Gower Street, London, WC1E 6BT, London, UK.

k. Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Units 1501-1502, 1512-1518, 15/F

Building 17W, 17 Science Park W Ave, Science Park, Hong Kong, PR China.

l. Department of Medical Physics, Department of Medicine, University of Wisconsin School of Medicine

and Public Health, 111 Highland Ave, Room 1005, Madison, Wisconsin, USA, 53705.

m. William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, Wisconsin, USA,

53705.

n. Department of Kinesiology, University of Wisconsin School of Education, 1300 University Avenue, 285

Medical Sciences Center, Madison, Wisconsin, USA, 53706.

* Correspondence:

Adam J Paulsen

J5/M154, Clinical Science Center

600 Highland Avenue

Madison, WI 53792

apaulsen@medicine.wisc.edu

ABSTRACT:

INTRODUCTION: Relationships between core Alzheimer's disease (AD) biomarker accumulation and cognitive decline are well-established and the literature generally suggests a favorable relationship of cardiorespiratory fitness (CRF) on AD biomarker accumulation and cognition. Differences in risk of biomarker status conversion or accumulation rates by CRF, or their potential interactive relationships with cognitive decline remain largely unknown.

METHODS: Participants (N=533; Mean$_{AGE}$=65, 70% female) from the Wisconsin Alzheimer's Disease Research Center and the Wisconsin Registry for Alzheimer's Prevention underwent serial blood draws, and cognitive and imaging assessments (Mean$_{Follow-up}$=6.0 years). PET imaging of amyloid-β (Aβ) and tau (T) and plasma phosphorylated tau-217 (pTau-217) were used to determine biomarker status (+/-). Sex-specific estimated CRF (eCRF) tertiles were created using a validated equation. Kaplan-Meier survival curves and Cox-proportional hazards models characterized the risk of becoming biomarker-positive. Linear mixed effects models estimated associations between baseline eCRF and core AD biomarker accumulation and whether eCRF modified relationships between biomarker accumulation and cognitive decline. Analyses were stratified by biomarker +/- status.

RESULTS: No significant relationships were observed between eCRF and biomarker trajectories. However, those in the high eCRF group who were also Aβ- (HR[95%CI]=0.42[0.20, 0.88]) and pTau-217- (HR[95%CI]=0.45[0.21, 0.97]) at baseline had a significantly lower risk of becoming biomarker-positive. There was a significant attenuation of the detrimental relationship between Aβ accumulation and cognitive decline for those with high eCRF and Aβ+/T+.

DISCUSSION: While CRF did not influence core AD biomarker accumulation trajectories, high CRF did seem to protect against becoming biomarker-positive and attenuate the known deleterious relationship between biomarker accumulation and cognitive decline in Aβ+/T+.

Abbreviations: **Aβ** = amyloid-β; **AD** = Alzheimer's disease; **APOE ε4+** = APOE ε4 allele carriage; **BMI** = body mass index; **CRF** = cardiorespiratory fitness, **DVR** = distribution volume ratio; **eCRF** = estimated cardiorespiratory fitness, **HR** = hazard ratio; **LME** = linear mixed effects; **NFT** = neurofibrillary tangle; **PA** = physical activity; **PACC** = Preclinical Alzheimer's Cognitive Composite; **PET** = positron emission tomography; **PiB** = ^{11}C-Pittsburgh Compound B; **pTau** = phosphorylated tau; **RAVLT** = Rey Auditory Verbal Learning Test Delayed Recall, **SD** = standard deviation; **SNAP** = suspected non-Alzheimer's disease pathophysiology; **SUVR** = standard uptake value ratios; **T** = tau; **TMTB** = Trails Making Test B; **VO$_{2peak}$** = peak oxygen consumption calculated for the present study using a validated eCRF equation; **WADRC** = Wisconsin Alzheimer's Disease Research Center; **WRAP** = Wisconsin Registry for Alzheimer's Prevention

1. Introduction:

Accumulation of amyloid-β (Aβ) and tau (T), neuropathologic hallmark proteins of Alzheimer's disease (AD), begins decades prior to clinically relevant symptoms, making them the earliest known markers of AD-related pathological changes.[1–5] Phosphorylated tau (pTau) has also recently been suggested as a key biomarker for the diagnosis of AD, even in preclinical stages.[1,2,6,7] The timing of these pathologic changes is helpful in identifying people at greatest risk while in the preclinical stages along the AD dementia continuum and are highly relevant for research aimed at identifying preventative strategies for AD.[2,3,8]

Age, genetics, and family history of AD are the greatest known risk factors for AD.[9] Conversely, existing literature suggests that higher levels of physical activity (PA) and better cardiorespiratory fitness (CRF) may positively alter both AD neuropathological progression[10–13] and age-related cognitive decline[10,13–17], thereby reducing risk for AD and related dementias. AD biomarker profiles of highly fit individuals seem to be less adversely impacted by genetic risk compared to those less fit.[12] Moreover, the literature suggests that the negative effects of Aβ accumulation on cognitive function are mitigated by higher CRF, and conversely, that downstream effects of physical inactivity moderate the effect of Aβ on cognitive decline.[15,16] The majority of this literature is cross-sectional in nature and limited by modest sample sizes, leaving a knowledge gap in our understanding of the impact of CRF on AD biomarker accumulation. Moreover, trajectories of AD biomarker accumulation differ based on biomarker positivity status (i.e., participants who are already Aβ+ tend to accumulate Aβ at a faster rate than those who are Aβ-, who may not accumulate Aβ at all).[18,19]

The present study examines the relationship between baseline CRF with trajectories of core AD biomarker accumulation, namely Aβ and tau measured using positron emission tomography (PET), and pTau-217 measured in plasma, and the risk of conversion to biomarker positivity for those who were

negative at baseline. Additionally, we investigate the potential modification of the relationships between accumulation trajectories of each of these core AD biomarkers and cognitive decline by CRF. Importantly, the present study examines the aforementioned relationships based on AD biomarker status (+/-).

2. Methods:

2.1 Participants. The present sample included 533 participants from the Wisconsin Registry for Alzheimer's Prevention (WRAP) and the Wisconsin Alzheimer's Disease Research Center (WADRC), two prospective cohorts enriched for parental history of AD at enrollment, consisting of more than 2000 middle-aged and older adults. Detailed descriptions of enrollment criteria have been previously published.[20,21] The current sample was comprised of participants with available data of interest, predominantly white (92%; 5% Black/African American; 3% all other groups), on average college educated, and cognitively unimpaired at baseline. Participants ranged in age between 46-89 years, with a mean follow-up (SD) of 6.0 (3.9) years (number of visits ranging from 1 to 7). All participants provided written informed consent prior to participation and all procedures were approved by the University of Wisconsin Health Sciences Institutional Review Board.

2.2 Cardiorespiratory fitness. An estimated CRF (eCRF) was calculated using a validated equation,[22] which accounts for age, sex, body mass index, resting heart rate, and self-reported PA:

$$\text{eCRF} = 3.5 \times [18.07 + (2.77 \times \text{Sex}_{(M=1, F=0)}) - (0.10 \times \text{Age}) - (0.17 \times \text{BMI}) - (0.03 \times \text{Resting Heart Rate}) + (\text{PA score})],$$

with a resulting estimate of VO_{2peak} in mL/kg/min. BMI was calculated as weight in kilograms divided by height in meters squared. Resting heart rate was measured using a GE Dinamap Pro 400 V2 Vital Signs Monitor (GE Medical Systems Information Technologies, Inc., Milwaukee, WI). Responses to

questionnaires characterizing participants' habitual activity levels (duration, intensity, and frequency per week) were used to calculate the PA score as previously described.[22–24] Briefly, the PA score incorporates the characteristics of habitual PA to assign five distinct PA levels with scores assigned to each level ranging from 0 to 3.03. In addition to the continuous measure of eCRF, a categorical eCRF variable was created by defining sex-specific tertile cut-points across all participants in WRAP/WADRC, which were then applied to the current sample to create low, middle, and high eCRF groups.

2.3 Biomarker Measurements. Aβ burden was measured using ^{11}C-Pittsburgh Compound B (PiB) PET imaging. PiB acquisition and postprocessing protocols have been previously detailed.[25] Briefly, participants underwent PiB imaging with a 6-minute transmission scan after bolus injection and a 70-minute dynamic scan. Cortical Aβ burden was quantified based on derived distribution volume ratio (DVR) maps using the Logan method with cerebellar gray matter as reference.[25] Amyloid positivity (Aβ+) was defined by a global cortical DVR>1.19.[26] Tau was measured using ^{18}F-MK-6240 PET tracer. Acquisition and postprocessing has been previously described.[4] Briefly, standard uptake value ratios (SUVR) were calculated following a 20-minute dynamic acquisition scan. Tau positivity (T+) was defined by tracer uptake in the entorhinal cortex where neurofibrillary tangles (NFT) are expected to first occur (entorhinal SUVR>1.27) or regional tau positivity in NFT associated regions corresponding to Braak staging.[5,27,28]

Participants provided blood samples at each study visit from which pTau-217, which is indicative of Aβ positivity and may also reflect the entire AD pathological process,[29–31] was assayed using ALZpath (ALZpathDX, Carlsbad, CA) at the Clinical Neurochemistry Laboratory in the University of Gothenburg, Sweden. Detailed information on the collection and processing of samples and quantification of pTau-

217 has been previously published.[30,31] A binary pTau-217 +/- status was created using a previously determined center-wide reference cut-point of >0.63 pg/mL.[29]

Analyses including pTau-217 (N=445) and tau-PET (N=457) had slightly smaller sample sizes due to missingness of those measures.

2.4 Neuropsychological Assessment. Participants undergo biannual neuropsychological assessment as part of their WRAP/WADRC participation. The present study employed a modified Preclinical Alzheimer's Cognitive Composite (PACC-3) score, comprised of the Rey Auditory Verbal Learning Test Delayed Recall (RAVLT), the Wechsler Memory Scale Logical Memory II, and the Trail Making Test Part B (TMTB), as the utility of global composite scores is superior to performance on individual tests when assessing longitudinal cognitive decline.[32,33] The composite score was z-transformed across the entire WRAP and WADRC cohort for analyses purposes, so that scores among a cognitively unimpaired sample had an approximately normal distribution with mean=0 and SD=1.

2.5 Statistical Analyses. All analyses were conducted using RStudio version 2023.12.1+402 (Posit Software, PBC). Analyses were stratified by Aβ-PET status (Aβ- or Aβ+) at baseline given that biomarker accumulation trajectories tend to differ based on baseline Aβ positivity status, and Aβ is considered the earliest indication of AD pathological change.[18,19,27,34] Differences in baseline characteristics by Aβ+/- status were determined using t-tests for continuous variables and chi-squared tests for categorical variable. Analyses of change in cognition were conducted stratified by Aβ and tau+/- status at any timepoint (i.e., Aβ-T- were never positive and Aβ+T+ were positive for both biomarkers at their most recent visit) as the combined pathology confers the greatest risk of cognitive change[27,35,36] and few participants were T+ at baseline in the current sample, limiting power for stratified analyses. The

resultant groups were Aβ-T-, Aβ+T-, Aβ-T+, and Aβ+T+. Statistical significance was determined with a two-tailed $p<0.05$.

Linear mixed effects (LME) models were constructed by including baseline eCRF, years of follow-up for biomarker measurement, and their interaction to investigate whether rates of biomarker accumulation over time differ based on eCRF. This relationship was tested using continuous eCRF (per SD increase) and by eCRF group with the low fitness group as the reference. All models were adjusted for baseline age, sex, years of education, *APOE* ε4 carrier status, parental history of AD, years of follow-up, and random intercept and slope per participant.

To evaluate the relationship between eCRF and conversion to biomarker positivity during follow-up for those who were biomarker negative at baseline, Kaplan-Meier survival curves were constructed by eCRF group. Additional Cox-Proportional Hazards models were created to estimate the difference in risk of conversion to biomarker positivity by Aβ-PET, tau-PET, and plasma pTau-217 respectively for participants who were negative for each biomarker at baseline controlling for age, sex, years of education, *APOE* ε4 carrier status, and parental history of AD. Coefficients from these models were exponentiated to provide Hazard Ratios (HR) detailing the difference in risk of conversion by eCRF group.

LME models were used to evaluate the modification of the association between time-varying biomarker levels (per SD) and cognitive trajectory (PACC-3 score) by eCRF. These models were stratified by Aβ and tau status at any time point (Aβ-T-, Aβ+T-, Aβ-T+, and Aβ+T+) due to the potential synergistic effects of Aβ and T on cognitive change.[27,34–36] Models included baseline eCRF, biomarker level, years of follow-up, interaction terms between each of these variables, and a three-way interaction term between baseline eCRF, biomarker level, and years of follow-up. This three-way interaction term provided the

coefficient of interest indicating differing rates of cognitive change per SD change in biomarker per year

of follow-up based on eCRF group. These models were adjusted for baseline age, sex, years of education,

APOE ε4 carrier status, parental history of AD, and random intercept and slope per participant.

3. Results:

3.1 Participants – Baseline characteristics of the full sample and the Aβ+/- (by PiB-PET) sub-samples are

provided in **Table 1**. The entire sample (N=533) was 70% female and majority of participants (79%) were

Aβ- at baseline. These participants were younger, less likely to be *APOE* ε4 carriers or have a parental

history of AD compared to those Aβ+ at baseline (all $ps \leq 0.01$; **Table 1**). Significant differences in baseline

AD biomarker levels were observed between Aβ+ and Aβ- groups (all $ps < 0.001$). The Aβ+ group also had

significantly lower baseline PACC3 scores ($p < 0.001$).

3.2 eCRF and biomarker trajectories. Aβ accumulation rates based on global cortical PiB-PET DVR scores

(all $ps \geq 0.08$; **Table 2**) or by plasma pTau-217 (all $ps \geq 0.25$; **Table 2**) did not significantly differ by eCRF

group regardless of baseline Aβ status. This lack of association between eCRF and pTau-217 remained

when analyses were re-stratified by baseline pTau-217 status (pTau-217+/-; data not shown). There were

no significant differences in accumulation rates of tau-PET by eCRF. (all $ps \geq 0.15$; **Table 2**). This lack of

association between eCRF and tau remained unchanged when re-stratifying analyses by baseline T+/-

status based on tau-PET (data not shown).

3.3 eCRF and biomarker conversion. For those Aβ- at baseline, the high eCRF group had a lower risk of

conversion to Aβ+ status over the course of follow-up, with only 5.8% of those in the high compared to

10.8% in the low eCRF group converting. A Kaplan-Meier survival analysis confirmed a significantly lesser

risk of conversion to Aβ+ status over the course of follow up for the high ($p < 0.001$), but not the middle

(p=0.18), eCRF group; **Figure 1**. Cox-proportional hazards model, adjusted for age, sex, years of education, *APOE* e4 carrier status, and parental history of AD, yielded similar results, whereby the high eCRF group had lesser risk (HR [95% CI = 0.42 [0.20, 0.88]) of conversion to Aβ+ compared to low eCRF group, indicating a 58% decrease in risk of conversion. No significant differences in risk were observed for the middle compared to the low eCRF group (HR [95%CI] = 0.85 [0.46, 1.54]; **Table 3**). Among those who were pTau-217- at baseline, the high eCRF group had a significantly lower risk of conversion via both Kaplan-Meier survival analysis (p=0.04) and Cox proportional hazards model (HR[95%CI]= 0.45 [0.20, 0.97]), which revealed a 55% risk reduction**; Figure 1, Table 3**. For those who were T- at baseline, Kaplan-Meier survival analysis indicated a trend toward better survival (non-conversion to T+); for both the middle and the high eCRF groups (all *ps*= 0.07); **Figure 1**. This association was not confirmed, however, by multivariable adjusted Cox proportional hazards modeling (all *ps*≥0.11; **Table 3**).

3.4 eCRF, biomarker trajectories and cognitive change. In analyses stratified by Aβ/T status, we found a positive association between eCRF and cognitive trajectories among those who were Aβ+/T+, where high eCRF attenuated the negative association between higher levels of Aβ (per SD increase) and steeper cognitive decline; **Table 4, Figure 2**. Using estimates from the full model to calculate rates of cognitive change by eCRF holding covariates constant, the low eCRF group among Aβ+T+ had a decline in cognitive performance of -0.132/year per SD increase in Aβ, whereas those in the middle and high eCRF groups had significantly slower rates of cognitive decline (-0.023/year and -0.013/year per SD increase in Aβ, respectively, all *ps<0.05*). No significant relationships were observed between eCRF and cognitive decline for Aβ-T-, Aβ+T-, or Aβ-T+ groups (all *ps*≥0.24).

There were no significant associations between eCRF and cognitive decline with increasing plasma pTau-217 in Aβ-T- or Aβ+T- groups (all *ps*≥0.22). A significant negative association was observed in the Aβ-T+

group, whereby higher eCRF was associated with a steeper cognitive decline per SD increase in pTau-217

(p<0.01); **Table 4**. Among Aβ+T+, the middle and the high eCRF groups had slower cognitive decline

compared to the low eCRF, though this association did not reach statistical significance (all ps≥0.17),

Table 4, **Figure 2**.

No statistically significant relationships were observed between eCRF and cognitive decline with

increasing levels of tau-PET (all ps≥0.19), albeit there was a non-significant trend for less cognitive

decline with increasing tau burden in the middle and high eCRF groups among Aβ+T+ (all ps≥0.27), **Table**

4, **Figure 2**.

4. Discussion:

In the current sample of middle-aged and older adults who were cognitively unimpaired at baseline from

a cohort enriched for AD risk at enrollment, AD biomarker (Aβ and tau by PET, and plasma pTau-217)

accumulation rates did not differ based on CRF. In those Aβ- at baseline, however, a 58% decrease in risk

of conversion to Aβ+ status over the course of follow-up was observed for those with high compared to

low CRF. Those with high CRF also had a 55% decrease in risk of conversion to pTau-217+. Importantly,

the relationship between AD biomarker accumulation and cognitive decline seems to differ by CRF, such

that for Aβ+T, high CRF was associated with slower rates of cognitive decline per SD increase in

biomarkers.

The extant literature supports a protective effect of PA or CRF on brain health.[10,11,13,17,37] Higher

levels of PA and higher CRF are associated with lower levels of core AD biomarkers,[11,12,38] although,

some recent findings suggest no associations with biomarker deposition.[37,39,40] Our current results

are in line with the more recent literature[37,39,40]– we too report no relationship between CRF and the

rates of Aβ (by PET or plasma pTau-217) or tau (MK-6240 PET) accumulation. Of note, we stratified our sample based on baseline Aβ status, which no study reporting a significant association between PA or CRF and accumulation of core AD neuropathology previously accounted for. However, in those with high CRF who were Aβ- at baseline, we observed a ~60% reduction in the risk of conversion to Aβ+ whether by PET or plasma pTau-217, both of which are indicative of clinically relevant Aβ accumulation. This is an important finding, as prevention or delay of accumulation to a point of clinical relevance could significantly reduce future negative sequalae of AD.

While CRF did not confer resilience against AD biomarker accumulation in our sample, we did see potential CRF contributions to resilience against cognitive decline. The relationship between AD biomarker accumulation and cognitive decline is well-established in the literature, whereby higher levels of AD biomarkers are associated with poorer cognitive performance[27,41] and precipitate cognitive decline.[30,34,35,42] Our current findings suggest that CRF may offset the deleterious effects of core AD biomarker accumulation on cognitive decline. Those who were Aβ+T+ but concomitantly had higher eCRF declined cognitively at a slower rate even when experiencing increasing levels of AD biomarkers. Although this finding was only statistically significant with regards to Aβ, similar associations were observed with pTau-217 and tau-PET accumulation and warrant further investigation. Conversely, our finding of an unexpected deleterious association between high eCRF and cognitive decline in the Aβ-T+ group with increasing pTau-217, could indicate that once a threshold of tau accumulation is crossed (T+), CRF may no longer confer resilience against cognitive decline, though due to the relatively small sample size in this group as well as the other subgroups (i.e., Aβ-T+ high eCRF), caution should be used in interpretation of this finding. Furthermore, while pTau-217 is considered a marker of brain Aβ, it is also indicative of other non-Aβ-related changes across the AD continuum, which might account for the disparity in the results between PiB-PET and plasma pTau-217.[29] Additionally, research has suggested

that the cognitive trajectory of people with the Aβ-T+ biomarker profile, frequently termed suspected

non-Alzheimer's disease pathophysiology (SNAP),[43,44] follows more closely with those who are Aβ-T-

than with those on the AD continuum,[45,46] though this relationship may be dependent on additional

measures of neurodegeneration.[47] Our findings may reflect differences in the pathological processes

that contribute to non-AD accumulation of tau, which may be robust to potential protective effects of

CRF, or could be due to the unknown levels of other neurodegenerative markers (i.e., brain atrophy,

neurofilament light chain),[43,47] that may be present in A-T+ but are outside the scope of the present

study. This warrants further investigation with a larger sample of A-T+ individuals and with

differentiation by additional neurodegenerative biomarkers.

While others have reported PA to be associated with better cognitive performance, they did not observe

an attenuation of the adverse relationship between core AD pathology and cognition or did not evaluate

the potential effect modification that CRF may have on this relationship.[14,24,48–50] Our current

findings suggest that the deleterious relationship between accumulation of core AD neuropathology and

cognitive decline could potentially be mitigated through exercise interventions and maintenance of CRF

with age. In our sample, higher CRF seemed to be most beneficial for those participants who were

Aβ+T+ . Literature suggests that the "chronicity" of Aβ and tau positivity confers greater risk for and may

have synergistic effects on cognitive decline.[5] Hence, the potential resilience conferred by CRF to

those Aβ+T+ would be of utmost interest as a potential clinical intervention or preventative strategy.

One potential limitation of the current study is the use of an estimated measure of CRF, which relies on

questionnaire data that could be prone to recall or reporting biases. Even so, this measure correlates

well with VO_{2peak}, the gold standard measure of CRF. [23,24] The WRAP and WADRC cohorts are

predominantly highly educated and non-Hispanic white, making generalizability of the current findings

15

unknown. Nonetheless, our findings are of value given the current lack of longitudinal studies on this

and similar topics. The foregoing limitations notwithstanding, the WRAP and WADRC are prospective

studies of well-characterized cohorts with high participation and retention rates and standardized

procedures. This longitudinal design allows for characterization of biomarker trajectories and cognitive

change, which is paramount to understanding the temporal relationships between potentially modifiable

factors and AD-relevant outcomes.

4.1 *Conclusions*

Overall, our findings suggest that while CRF may not have an impact on the rate of accumulation of core

AD biomarkers, high CRF does seem to reduce the risk of conversion from $A\beta$- to $A\beta$+. Perhaps more

importantly, higher CRF seems to attenuate the otherwise deleterious relationship between core AD

biomarker accumulation and cognitive decline, specifically for those at highest risk for AD ($A\beta$+T+).

Together, our findings suggest an important role for CRF in relation to AD hallmark pathologic changes

and offer a potential avenue for intervention.

5. Declarations of Interest

Declarations of Interest: Dr. Ozioma Okonkwo receives grant support from the NIH. He also serves as the

treasurer of the International Neuropsychological Society. He is also a guest editor of this journal but was

not involved in the peer-review process of this article nor had access to any information regarding its

peer-review. Drs. Ira Driscoll, Yue Ma, and Tobey Betthauser receive grant support from the NIH. Dr.

Cynthia Carlsson receives grant support from the NIH, Department of Veterans Affairs, NIH/Lilly,

NIH/Eisai, NIH/Cognition Therapeutics, and research medication support from Amarin Corporation. Dr.

Kaj Blennow has served as a consultant, on advisory boards, or on data-monitoring committees for

Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena,

Roche Diagnostics, and Siemens Healthineers; has served on data monitoring committees for Julius

Clinical and Novartis; has given lectures, produced educational materials, and participated in educational

programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and is a co-founder of

Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program

(outside submitted work). Dr. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at

the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356,

#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation

programme under grant agreement No 101053962, and Swedish State Support for Clinical Research

(#ALFGBG-71320). Dr. Zetterberg has served at scientific advisory boards and/or as a consultant for

Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics,

AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo

Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs,

reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures

sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and

WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the

GU Ventures Incubator Program (outside submitted work). Dr. Sanjay Asthana receives grant support

from the NIH. He also receives royalty as an editor of a textbook entitled, Hazzard's Geriatrics and

Gerontology; McGraw Hill, Publisher. Dr. Sterling Johnson receives grant support from the NIH. He also

serves as a consultant and on advisory boards for ALZPath and Enigma Biosciences. All other authors

have no relevant disclosures to report.

6. Consent Statement

Written informed consent was provided by all participants prior to study participation and approval was

obtained from the institutional review board.

17

7. Funding

8. Author Contributions

AJP, BMB, and OCO designed the experiments. Data for the current project were provided by the

laboratories of OCO, SCJ, SA, TJB, CLG, CMC, KB, and HZ. SRL and BMB collected and processed

cardiorespiratory fitness data. ID, MPG, BTC and DBC were consulted on data acquisition, analyses or

interpretation based on their respective expertise. AJP analyzed the data, wrote the manuscript, and

prepared figures. All authors edited, revised, and approved the final version of the manuscript.

9. Acknowledgments

10. References:

1. Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals

   from families with autosomal dominant Alzheimer's disease: a longitudinal study. *Lancet Neurol.*

   2018;17(3):241-250. doi:10.1016/S1474-4422(18)30028-0

2. Jack CR, Andrews SJ, Beach TG, et al. Revised criteria for the diagnosis and staging of Alzheimer's

   disease. *Nat Med.* 2024;30(8):2121-2124. doi:10.1038/s41591-024-02988-7

3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease:

   recommendations from the National Institute on Aging-Alzheimer's Association workgroups on

   diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement J Alzheimers Assoc.*

   2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003

4. Betthauser TJ, Cody KA, Zammit MD, et al. In Vivo Characterization and Quantification of

   Neurofibrillary Tau PET Radioligand[18] F-MK-6240 in Humans from Alzheimer Disease Dementia to

   Young Controls. *J Nucl Med.* 2019;60(1):93-99. doi:10.2967/jnumed.118.209650

5. Cody KA, Langhough RE, Zammit MD, et al. Characterizing brain tau and cognitive decline along the

   amyloid timeline in Alzheimer's disease. *Brain.* 2024;147(6):2144-2157.

   doi:10.1093/brain/awae116

6. Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau,

   amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat Med.*

   2020;26(3):398-407. doi:10.1038/s41591-020-0781-z

7. Barthélemy NR, Salvadó G, Schindler SE, et al. Highly accurate blood test for Alzheimer's disease is

   similar or superior to clinical cerebrospinal fluid tests. *Nat Med.* 2024;30(4):1085-1095.

   doi:10.1038/s41591-024-02869-z

8.   Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of

       Alzheimer's disease. *Alzheimers Dement J Alzheimers Assoc*. 2018;14(4):535-562.

       doi:10.1016/j.jalz.2018.02.018

9.   2024 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2024;20(5):3708-3821.

       doi:10.1002/alz.13809

10. Dougherty RJ, Jonaitis EM, Gaitán JM, et al. Cardiorespiratory fitness mitigates brain atrophy and

       cognitive decline in adults at risk for Alzheimer's disease. *Alzheimers Dement Diagn Assess Dis*

       Monit. 2021;13(1):e12212. doi:10.1002/dad2.12212

11. Okonkwo OC, Schultz SA, Oh JM, et al. Physical activity attenuates age-related biomarker alterations

       in preclinical AD. *Neurology*. 2014;83(19):1753-1760. doi:10.1212/WNL.0000000000000964

12. Schultz SA, Boots EA, Darst BF, et al. Cardiorespiratory fitness alters the influence of a polygenic risk

       score on biomarkers of AD. *Neurology*. 2017;88(17):1650-1658.

       doi:10.1212/WNL.0000000000003862

13. Tan ZS, Spartano NL, Beiser AS, et al. Physical Activity, Brain Volume, and Dementia Risk: The

       Framingham Study. *J Gerontol A Biol Sci Med Sci*. 2017;72(6):789-795. doi:10.1093/gerona/glw130

14. Buchman AS, Yu L, Wilson RS, et al. Physical activity, common brain pathologies, and cognition in

       community-dwelling older adults. *Neurology*. 2019;92(8):e811-e822.

       doi:10.1212/WNL.0000000000006954

15. Clark LR, Koscik RL, Allison SL, et al. Hypertension and obesity moderate the relationship between β-

       amyloid and cognitive decline in midlife. *Alzheimers Dement J Alzheimers Assoc*. 2019;15(3):418-

       428. doi:10.1016/j.jalz.2018.09.008

16. Schultz SA, Boots EA, Almeida RP, et al. Cardiorespiratory Fitness Attenuates the Influence of

    Amyloid on Cognition. *J Int Neuropsychol Soc*. 2015;21(10):841-850.

    doi:10.1017/S1355617715000843

17. Vesperman CJ, Wang R, Schultz SA, et al. Cardiorespiratory fitness and cognition in persons at risk for

    Alzheimer's disease. *Alzheimers Dement Diagn Assess Dis Monit*. 2022;14(1):e12330.

    doi:10.1002/dad2.12330

18. Landau SM, Horng A, Jagust WJ, For the Alzheimer's Disease Neuroimaging Initiative. Memory

    decline accompanies subthreshold amyloid accumulation. *Neurology*. 2018;90(17):e1452-e1460.

    doi:10.1212/WNL.0000000000005354

19. Hatashita S, Wakebe D. Longitudinal assessment of amyloid-beta deposition in initially amyloid-

    negative non-demented individuals with [11C]-PIB PET imaging. *Medicine (Baltimore)*.

    2021;100(35):e27055. doi:10.1097/MD.0000000000027055

20. Asthana S, Golden RN. Wisconsin Alzheimer's Disease Research Center-Notable Discoveries and

    Accomplishments in Dementia Research. *WMJ Off Publ State Med Soc Wis*. 2024;123(1):62-63.

21. Johnson SC, Koscik RL, Jonaitis EM, et al. The Wisconsin Registry for Alzheimer's Prevention: A

    review of findings and current directions. *Alzheimers Dement Diagn Assess Dis Monit*.

    2018;10(1):130-142. doi:10.1016/j.dadm.2017.11.007

22. Jurca R, Jackson AS, LaMonte MJ, et al. Assessing Cardiorespiratory Fitness Without Performing

    Exercise Testing. *Am J Prev Med*. 2005;29(3):185-193. doi:10.1016/j.amepre.2005.06.004

23. Boots EA, Schultz SA, Oh JM, et al. Cardiorespiratory fitness is associated with brain structure, cognition, and mood in a middle-aged cohort at risk for Alzheimer's disease. *Brain Imaging Behav*. 2015;9(3):639-649. doi:10.1007/s11682-014-9325-9

24. McIntyre CC, Gaitán JM, Edmunds KJ, et al. Insulin Homeostasis Mediates the Relationship Between Cardiorespiratory Fitness and Cognitive Speed in Aging Adults. Craft S, ed. *J Alzheimers Dis*. 2023;93(2):577-584. doi:10.3233/JAD-221249

25. Johnson SC, Christian BT, Okonkwo OC, et al. Amyloid burden and neural function in people at risk for Alzheimer's Disease. *Neurobiol Aging*. 2014;35(3):576-584. doi:10.1016/j.neurobiolaging.2013.09.028

26. Racine AM, Clark LR, Berman SE, et al. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. *J Alzheimers Dis JAD*. 2016;54(4):1395-1408. doi:10.3233/JAD-160528

27. Betthauser TJ, Koscik RL, Jonaitis EM, et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. *Brain*. 2020;143(1):320-335. doi:10.1093/brain/awz378

28. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol (Berl)*. 2006;112(4):389-404. doi:10.1007/s00401-006-0127-z

29. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. *JAMA Neurol*. 2024;81(3):255. doi:10.1001/jamaneurol.2023.5319

30. Du L, Langhough RE, Wilson RE, et al. Longitudinal plasma phosphorylated-tau217 and other related

    biomarkers in a non-demented Alzheimer's risk-enhanced sample. *Alzheimers Dement*.

    2024;20(9):6183-6204. doi:10.1002/alz.14100

31. Jonaitis EM, Janelidze S, Cody KA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer's

    disease. *Brain Commun*. 2023;5(2):fcad057. doi:10.1093/braincomms/fcad057

32. Jonaitis EM, Koscik RL, Clark LR, et al. Measuring longitudinal cognition: Individual tests versus

    composites. *Alzheimers Dement Diagn Assess Dis Monit*. 2019;11(1):74-84.

    doi:10.1016/j.dadm.2018.11.006

33. Sherman EMS, Tan JE, Hrabok M. *A Compendium of Neuropsychological Tests: Administration, Tests,*

    Norms, and Commentary. Fourth edition. Oxford University Press; 2020.

34. Koscik RL, Betthauser TJ, Jonaitis EM, et al. Amyloid duration is associated with preclinical cognitive

    decline and tau PET. *Alzheimers Dement Diagn Assess Dis Monit*. 2020;12(1).

    doi:10.1002/dad2.12007

35. Sperling RA, Mormino EC, Schultz AP, et al. The impact of amyloid-beta and tau on prospective

    cognitive decline in older individuals. *Ann Neurol*. 2019;85(2):181-193. doi:10.1002/ana.25395

36. Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively

    unimpaired individuals are at high risk for future cognitive decline. *Nat Med*. 2022;28(11):2381-

    2387. doi:10.1038/s41591-022-02049-x

37. Felisatti F, Gonneaud J, Palix C, et al. Role of Cardiovascular Risk Factors on the Association Between

    Physical Activity and Brain Integrity Markers in Older Adults. *Neurology*. 2022;98(20):e2023-e2035.

    doi:10.1212/WNL.0000000000200270

38. Yu F, Han SY, Salisbury D, et al. Feasibility and preliminary effects of exercise interventions on plasma biomarkers of Alzheimer's disease in the FIT-AD trial: a randomized pilot study in older adults with Alzheimer's dementia. *Pilot Feasibility Stud*. 2022;8(1):243. doi:10.1186/s40814-022-01200-2

39. Vidoni ED, Morris JK, Watts A, et al. Effect of aerobic exercise on amyloid accumulation in preclinical Alzheimer's: A 1-year randomized controlled trial. Bush AI, ed. *PLOS ONE*. 2021;16(1):e0244893. doi:10.1371/journal.pone.0244893

40. Sewell KR, Rainey-Smith SR, Pedrini S, et al. The impact of exercise on blood-based biomarkers of Alzheimer's disease in cognitively unimpaired older adults. *GeroScience*. 2024;46(6):5911-5923. doi:10.1007/s11357-024-01130-2

41. Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology*. 2018;91(9):e859-e866. doi:10.1212/WNL.0000000000006075

42. Levin F, Jelistratova I, Betthauser TJ, et al. In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. *Alzheimers Res Ther*. 2021;13(1):178. doi:10.1186/s13195-021-00918-0

43. Jack CR, Knopman DS, Chételat G, et al. Suspected non-Alzheimer disease pathophysiology — concept and controversy. *Nat Rev Neurol*. 2016;12(2):117-124. doi:10.1038/nrneurol.2015.251

44. Vos SJB, Delvenne A, Jack CR, Thal DR, Visser PJ. The clinical importance of suspected non-Alzheimer disease pathophysiology. *Nat Rev Neurol*. 2024;20(6):337-346. doi:10.1038/s41582-024-00962-y

45. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. *Lancet Neurol*. 2013;12(10):957-965. doi:10.1016/S1474-4422(13)70194-7

46. Erickson P, Simrén J, Brum WS, et al. Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease. *JAMA Neurol*. 2023;80(9):969. doi:10.1001/jamaneurol.2023.2338

47. Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. *Neurology*. 2020;95(1). doi:10.1212/WNL.0000000000009724

48. Meernik C, Eilat-Adar S, Leonard D, et al. Dietary patterns and cardiorespiratory fitness in midlife and subsequent all-cause dementia: findings from the Cooper Center Longitudinal Study. *Int J Behav Nutr Phys Act*. 2024;21(1):109. doi:10.1186/s12966-024-01663-x

49. Lerfald M, Allore H, Nilsen TIL, et al. Longitudinal Patterns of Systolic Blood Pressure, Diastolic Blood Pressure, Cardiorespiratory Fitness, and Their Association With Dementia Risk: The HUNT Study. Lipsitz LA, ed. *J Gerontol A Biol Sci Med Sci*. 2024;79(8):glae161. doi:10.1093/gerona/glae161

50. Nianogo RA, Rosenwohl-Mack A, Yaffe K, Carrasco A, Hoffmann CM, Barnes DE. Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US. *JAMA Neurol*. 2022;79(6):584-591. doi:10.1001/jamaneurol.2022.0976

Table 1: Baseline characteristics of the entire sample and by baseline Aβ status.

Baseline Characteristics	Baseline Aβ Status*			
	Overall (N=533)	Aβ- (N=423)	Aβ+ (N=110)	*p*-value[†]
Age (years), Mean (SD, range)	65.7 (7.8, 46 – 89)	64.7 (7.8, 46 – 89)	69.5 (6.4, 51 – 86)	**<0.001**
Sex, N(%)				
Female	375 (70.2)	305 (72.1)	70 (63.6)	
Male	158 (29.8)	118 (27.9)	40 (36.4)	0.11
Education (years), Mean (SD, range)	16.1 (2.2, 12 – 21)	16.1 (2.2, 12 – 21)	16.2 (2.1, 12 – 20)	0.53
***APOE* ε4 carrier status.** N (%)				
No	328 (61.6)	297 (70.2)	31 (28.2)	
Yes	205 (38.4)	126 (29.8)	79 (71.8)	**<0.001**
Parental history of dementia, N (%)				
No	159 (29.8)	136 (32.2)	23 (20.9)	
Yes, unknown dementia type	85 (15.9)	59 (13.9)	26 (23.6)	
Yes, AD	289 (54.3)	228 (53.9)	61 (55.5)	**0.01**
eCRF (ml/kg/min), Mean (SD, range)	25.9 (8.6, 3.4 – 46.7)	25.8 (8.6, 4.4 – 46.7)	26.6 (8.8, 3.4 – 43.3)	0.30
eCRF category, N (%)				
Low eCRF	198 (37.3)	157 (37.1)	41 (37.3)	
Middle eCRF	193 (36.1)	156 (36.9)	37 (33.6)	
High eCRF	142 (26.6)	110 (26.0)	32 (29.1)	0.75
Aβ-PET (DVR), Mean (SD, range)	1.16 (0.22, 0.85 – 2.07)	1.07 (0.05, 0.85 – 1.18)	1.53 (0.23, 1.20 – 2.07)	**<0.001**
pTau-217 (pg/mL), Mean (SD, range)	0.44 (0.32, 0.12 – 1.92)	0.31 (0.16, 0.12 – 1.92)	0.83 (0.38, 0.19 – 1.77)	**<0.001**
tau-PET (SUVR), Mean (SD, range)	1.16 (0.36, 0.70 – 2.88)	1.04 (0.70 – 1.76)	1.55 (0.53, 0.77 – 2.88)	**<0.001**
PACC-3 score, Mean (SD, range)	-0.002 (0.93, -5.11 – 1.85)	0.14 (0.74, -2.31 – 1.85)	-0.56 (1.34, -5.11 – 1.27)	**<0.001**

Bolding indicates a statistically significant result.

Abbreviations: Aβ = amyloid β, *APOE* = Apolipoprotein E , DVR = distribution volume ratio, eCRF=estimated cardiorespiratory fitness, pTau = phosphorylated tau, PACC-3 score= Preclinical Alzheimer's Cognitive Composite modified 3 test score, SD = standard deviation; SUVR= standardized uptake value ratio.

* Aβ+/- status determined by global cortical ^{11}C-Pittsburgh Compound B (PiB) distribution volume ratio (DVR) cut-point (cortical DVR > 1.19 at baseline examination).[26]

† Test for statistically significant difference between Aβ+/- groups at baseline using two-sample t-test and X^2 tests as appropriate.

Table 2: Difference in rates of biomarker accumulation (95% CI) per eCRF standard deviation and by eCRF group, stratified by baseline Aβ status.

		Aβ-	Aβ+
Aβ-PET			
N		423	110
Per SD eCRF*		-.000 (-.000, .000)	.001 (-.000, .002)
By eCRF category[†]			
	Low	Reference Group	
	Middle	.000 (-.005, .006)	.006 (-.012, .024)
	High	-.003 (-.009, .003)	.016 (-.001, .033)
Plasma pTau-217			
N		356	89
Per SD eCRF*		.000 (-.000, .000)	-.002 (-.005, .002)
By eCRF category[†]			
	Low	Reference Group	
	Middle	.005 (-.003, .014)	-.012 (-.087, .063)
	High	-.002 (-.011, .007)	-.036 (-.107, .035)
tau-PET			
N		362	95
Per SD eCRF*		-.000 (-.001, .000)	-.002 (-.005, .001)
By eCRF category[†]			
	Low	Reference Group	
	Middle	-.000 (-.010, .009)	-.024 (-.100, .052)
	High	-.007 (-.018, .003)	-.010 (-.083, .062)

Abbreviations: Aβ = amyloid-β ; *APOE* =Apolipoprotein E, CI = confidence interval, eCRF= estimated cardiorespiratory fitness, PET= positron emission tomography, pTau = phosphorylated tau, SD = standard deviation.
* Linear mixed effects models adjusted for baseline age, sex, years of education, *APOE* ε4 carrier status, parental history of AD, years of follow-up, and random intercept and slope per participant. Estimates represent difference in rate of biomarker accumulation based on interaction term between baseline eCRF (per SD) and years of follow-up.
[†] Linear mixed effects models adjusted for baseline age, sex, years of education, *APOE* ε4 carrier status, parental history of AD, years of follow-up, and random intercept and slope per participant. Estimates represent difference in rate of biomarker accumulation based on interaction term between baseline eCRF category and years of follow-up.

Table 3: Risk of conversion to biomarker positive status during follow-up by eCRF category among participants who were biomarker negative at baseline.*, †

Group	Risk of Conversion, HR (95% CI)		
	Aβ-PET	Plasma pTau-217	tau-PET
Low eCRF	Reference Group		
Middle eCRF	0.85 (0.46, 1.15)	0.61 (0.31, 1.17)	0.32 (0.08, 1.32)
High eCRF	**0.42 (0.20, 0.88)**	**0.45 (0.21, 0.97)**	0.38 (0.09, 1.56)

Bolding indicates a statistically significant result.

Abbreviations: Aβ= amyloid-β; CI= Confidence Interval, HR= Hazard Ratio, eCRF= estimated cardiorespiratory fitness, PET= positron emission tomography, pTau= phosphorylated tau.

* Aβ+ determined by cortical PiB-DVR>1.19[26]; pTau-217+ determined by pTau-217>0.63 pg/mL[29]; T+ determined by entorhinal ^{18}F-MK6240 SUVR > 1.27 or AD-like positive Braak staging in any region based on PET MK6240 uptake.[5,27,28]

† Based on Cox-proportional hazards models adjusted for baseline age, sex, years of education, *APOE* ε4 carrier status, parental history of AD, baseline eCRF. Estimates represent risk of conversion to biomarker positivity.

Table 4: Differences in rates of cognitive decline (PACC-3) by eCRF category, stratified by Aβ/T status.*, †

|	Aβ-T-	Aβ+T-	Aβ-T+	Aβ+T+
Cognitive rate of change per SD increase in Aβ-PET (difference in rate of change per year)	N=323	N=64	N=39	N=85
Low eCRF	Reference Group			
Middle eCRF	-.005 (-.042, .032)	-.141 (-.374, .093)	.072 (-.180, .325)	**.109 (0.001, .217)**
High eCRF	-.000 (-.036, .036)	-.083 (-.316, .149)	.038 (-.092, .168)	**.119 (.020, .217)**
Cognitive rate of change per SD increase in pTau-217 (difference in rate of change per year)	N=263	N=55	N=36	N=68
Low eCRF	Reference Group			
Middle eCRF	-.006 (-.046, .033)	-.119 (-.310, .072)	-.091 (-.507, .326)	0.070 (-.030, .169)
High eCRF	-.004 (-.047, .040)	-.073 (-.266, .121)	**-.330 (-.473, -.186)**	0.037 (-.034, 0.108)
Cognitive rate of change per SD increase in tau-PET (difference in rate of change per year)	N=265	N=49	N=37	N=80
Low eCRF	Reference Group			
Middle eCRF	-.042 (-.104, .020)	.015 (-.102, .133)	-.252 (-.683, .179)	.083 (-.119, .285)
High eCRF	-.003 (-.062, .057)	.038 (-.085, .161)	-.079 (-.476, .317)	.075 (-.059, .210)

Bolding indicates a statistically significant result.

Abbreviations: Aβ = amyloid-β, AD= Alzheimer's disease, *APOE* = Apolipoprotein E, eCRF = estimated cardiorespiratory fitness, pTau = phosphorylated tau, PACC-3 score= Preclinical Alzheimer's Cognitive Composite modified 3 test score, PiB DVR= [11]C Pittsburgh Compound B distribution volume ratio, SUVR= standardized uptake value ratio.

*Aβ+ determined by cortical PET PiB DVR > 1.19; T+ determined by entorhinal ^{18}F-MK6240 SUVR > 1.27 or positive Braak staging in any region based on PET MK6240 uptake.

† Models adjusted for baseline age, sex, years of education, *APOE* ε4 carrier status, parental history of AD, baseline eCRF, years of follow-up, and random intercept per participant. Estimates represent difference in rate of change in PACC-3 score per SD increase in biomarker estimated by a three-way interaction term between baseline eCRF, years of follow-up, and z-scored biomarker level.

Figure 1: Kaplan-Meier curves depicting risk of becoming positive for core AD biomarkers over the course of follow-up among participants who were biomarker negative at baseline by eCRF group. Significantly lower risk of becoming positive for Aβ by PET (*p*=<0.001) and pTau-217 (*p*=0.04) was observed for high (but not the middle) compared to low eCRF group. A trend for lower risk of conversion to T+ was observed for the middle and high eCRF groups compared to the low eCRF group, though these relationships were not statistically significant (all *ps*>0.05).

A: Aβ+ defined by a cortical PET-PiB DVR > 1.19.
B: pTau-217+ defined by plasma pTau-217> 0.63 pg/mL.
C: T+ defined by an entorhinal PET-^{18}F-MK6240 SUVR> 1.27 or regional tau positivity in NFT associated regions corresponding to Braak staging.

Abbreviations: Aβ = amyloid-β, eCRF = estimated cardiorespiratory fitness, NFT = neurofibrillary tangles, PiB DVR = [11]C Pittsburgh Compound B distribution volume ratio, PET= positron emission tomography, pTau = phosphorylated tau, SUVR = standard uptake value ratio.

31

Figure 2: Differences in rates of cognitive change (PACC3 score) in Aβ+/T+, by eCRF category and core AD biomarker levels. The figures display PACC3 trajectory for the low (faint lines) and high (bolded lines) eCRF groups with different levels of each biomarker (average and 1SD above average). A statistically significant interaction was observed for Aβ-PET (Panel A; $p<0.05$); those with both high eCRF and high Aβ (A; dark red line) experienced no decline in cognition, whereas those with low eCRF and high Aβ (panel A; pink line) experienced significant decline. Similar trends were observed for plasma pTau-217 (B; $p=0.31$) and tau-PET (C; $p=0.27$,), though these results were not statistically significant.

A: Aβ-PET

B: Plasma pTau-217

C: tau-PET

—— High eCRF, high biomarker (+1SD)

—— High eCRF, average biomarker

—— Low eCRF, high biomarker (+1SD)

—— Low eCRF, average biomarker

Aβ+/- status defined by a cortical PET-PiB DVR > 1.19, T+/- status defined by entorhinal PET-^{18}F-MK6240 SUVR>1.27 or regional tau positivity in NFT associated regions corresponding to Braak staging.

Abbreviations: Aβ = amyloid-β, eCRF = estimated cardiorespiratory fitness, NFT = neurofibrillary tangles, PET = positron emission tomography, PACC3 = Preclinical Alzheimer's Cognitive Composite modified 3 test score, PiB DVR = ^{11}C-Pittsburgh Compound B distribution volume ratio, SD = standard deviation, SUVR =standardized uptake value ratio.

Figures were created using the coefficients from multivariable linear mixed effects models, adjusted for baseline age, sex, years of education, *APOE* ε4 carrier status, parental history of AD, baseline eCRF, years of follow-up, random intercept, and random slope per participant.